Diagnosing and Managing Parkinson's Disease in Older Adults

Friday, May 31, 2019, 8:00 AM - Sunday, May 31, 2020, 11:59 PM

AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance. Nonmotor symptoms include autonomic, olfactory, or cognitive dysfunction, as well as neuropsychiatric symptoms, including psychosis with hallucinations and delusions. Symptoms of PD can be more severe in people whose disease onset occurs at an older age. This multidisciplinary activity will examine evidence-based recommendations for the diagnosis and management of the motor and neuropsychiatric signs and symptoms of PD in older adults.

There are no fees for participating in and receiving CME credit for this online activity.

This activity can be accessed by clicking here.

1. Demonstrate increased knowledge and competence in diagnosis and staging of PD;
2. Develop individualized treatment plans that optimally manage symptoms, decrease motor fluctuations in OFF periods, reduce the incidence of dyskinesia, and maximize patient functionality and QoL.
3. Nursing: After attending this session, the learner will be able to outline optimal treatment and management of Parkinson’s disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Faculty & Disclosure / Conflict of Interest Policy

According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity.  All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity. 

Medical Director & Program Planners

MCM Education

Kathleen Hines, Vice President, Editorial Services

University of Cincinnati Continuing Medical Education Office

Bruce Gebhardt, MD, Physician Reviewer-Compliance
Susan P. Tyler, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor MCM Education, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or MCM Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees professional development.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

This educational activity is supported by an educational grant from Acorda and Neurocrine Biosciences.